Cytochrome P450s in the development of target-based anticancer drugs
作者： Kedar Purnapatre , Sunil K. Khattar , Kulvinder Singh Saini
DOI: 10.1016/J.CANLET.2007.10.024
关键词:
摘要: Enzymes of the cytochrome P450 (CYP) superfamily are major determinants half-life and execute pharmacological effects many therapeutic drugs. In new drug discovery research, recombinant (human) CYPs also used for identifying active or inactive metabolites that could lead to increased potency toxicity a molecule. addition, CYP inhibition by anticancer drugs might adverse reactions, multiple-drug resistance, drug-drug interactions. During pre-clinical evaluation New Chemical Entity (NCE), large amounts purified required studying metabolism pharmacokinetic parameters. Therefore, present research efforts focused over-express these human in bacteria, yeast, insect mammalian cells, followed their purification on an industrial scale facilitate identification novel This review summarizes merits limitations expression systems optimized production individual isoforms, usefulness development target-based, safe efficacious NCEs treatment cancer.
elsevier.com
sci-hub.se 参考文章(105)
Susumu Imaoka, Takao Yamada, Toyoko Hiroi, Koji Hayashi, Toshiyuki Sakaki, Yoshiyasu Yabusaki, Yoshihiko Funae, Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochemical Pharmacology. ,vol. 51, pp. 1041- 1050 ,(1996) , 10.1016/0006-2952(96)00052-4
Mike W. Voice, Yan Zhang, C.Roland Wolf, Brian Burchell, Thomas Friedberg, Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo. Archives of Biochemistry and Biophysics. ,vol. 366, pp. 116- 124 ,(1999) , 10.1006/ABBI.1999.1192
David R. Nelson, Cytochrome P450 Nomenclature, 2004 Cytochrome P450 Protocols. ,vol. 320, pp. 1- 10 ,(2006) , 10.1385/1-59259-998-2:1
Caroline A. Lee, Thomas A. Kost, Cosette J. Serabjit-Singh, Recombinant baculovirus strategy for coexpression of functional human cytochrome P450 and P450 reductase. Methods in Enzymology. ,vol. 272, pp. 86- 95 ,(1996) , 10.1016/S0076-6879(96)72011-6
Cytochrome P450 protocols Methods of Molecular Biology. ,(1998) , 10.1007/978-1-62703-321-3
Charles L. Crespi, Bruce W. Penman, Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions Advances in pharmacology. ,vol. 43, pp. 171- 188 ,(1997) , 10.1016/S1054-3589(08)60205-7
David Kupfer, Shangara S. Dehal, CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Research. ,vol. 57, pp. 3402- 3406 ,(1997)
J. T. M. Buters, Magang Shou, F. J. Gonzalez, J. P. Hardwick, K. R. Korzekwa, cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification. Drug Metabolism and Disposition. ,vol. 23, pp. 696- 701 ,(1995)
Anders Edlund, Charlotta Otter, Tommy B. Andersson, Thore Johansson, Brith Leidvik, Mikael Berg, Marie Jönsson, Eva Jonsson, Collen M. Masimirembwa, Assar Bäckman, Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metabolism and Disposition. ,vol. 27, pp. 1117- 1122 ,(1999)
M V Relling, E G Schuetz, J D Schuetz, F J Gonzalez, J Nemec, K R Korzekwa, O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Molecular Pharmacology. ,vol. 45, pp. 352- 358 ,(1994)